Table 2. Response of TH-MYCN model of neuroblastoma to anti-vascular therapy.

Summary of tumor volume and magnetic resonance imaging (MRI) parameters determined prior to and 24h following treatment of tumor-bearing THMYCN mice with a single dose of 200mg/kg ZD6126 or vehicle, or prior to and 48h following daily treatment with 6mg/kg cediranib or vehicle.

	ZD6126				cediranib
	Control		Treated		Control		Treated
Parameter	Pre	24h	Pre	24h	Pre	48h	Pre	48h
Native relaxation times/rates 1
Volume (mm3)	867 ± 181	977 ± 222 (0.06)	944 ± 183	593 ± 115 (0.0001)	1218 ± 217	1546 ± 254 (0.0002)	1297 ± 215	1033 ± 174 (0.001)
T1 (ms)	1846 ± 29	1843 ± 28 (0.86)	1867 ± 32	1607 ± 31 (0.0001)	1878 ± 26	1943 ± 43 (0.20)	1807 ± 21	1667 ± 35 (0.00003)
T2 (ms)	63 ± 4	60 ± 2 (0.40)	77 ± 12	56 ± 3 (0.12)	71 ± 9	64 ± 4 (0.49)	66 ± 6	53 ± 3 (0.06)
R2* (s−1)	101 ± 7	98 ± 6 (0.43)	106 ± 7	123 ± 13 (0.25)	114 ± 7	114 ± 8 (0.29)	106 ± 6	131 ± 9 (0.004)
DCE MRI parameters 2
Volume (mm3)	1214 ± 346	1389 ± 423 (0.06)	966 ± 184	533 ± 113 (0.003)	1492 ± 418	1782 ± 483 (0.006)	1849 ± 220	1486 ± 173 (0.02)
IAUGC60 (mM Gd.min)	0.043 ± 0.008	0.093 ± 0.016 (0.07)	0.032 ± 0.005	0.052 ± 0.015 (0.25)	0.032 ± 0.010	0.061± 0.02 (0.22)	0.022 ± 0.004	0.017 ± 0.006 (0.37)
Ktrans (min−1)	0.072 ± 0.018	0.116± 0.015 (0.12)	0.057 ± 0.016	0.062 ± 0.023 (0.88)	0.059 ± 0.018	0.073 ± 0.02 (0.25)	0.027 ± 0.007	0.013 ± 0.004 (0.07)
Ve	0.073± 0.011	0.1 ± 0.005 (0.09)	0.056 ± 0.021	0.120 ± 0.024 (0.03)	0.062 ± 0.013	0.078 ± 0.012 (0.09)	0.058 ± 0.005	0.082± 0.022 (0.25)
EF (%)	98.3 ± 0.5	98.9 ± 0.4 (0.43)	90.8 ± 6.1	92.0 ± 5.7 (0.61)	94.1 ± 2.7	96.2 ± 1.5 (0.33)	93.7± 1.4	84.7± 4 (0.04

Data are presented as mean ± 1 standard error of the mean

¹(n=8,8 for study with ZD6126 and n=11,11 for study with cediranib,

²n=6,6 for study with ZD6126 and n=7,7 for study with cediranib). Numbers in parentheses show p-value (Student’s 2-tailed paired t-test).